BiotechTube
Home/Pipeline/LBS-007

LBS-007

Acute Myeloid Leukemia

Phase 1/2Active

Key Facts

Indication
Acute Myeloid Leukemia
Phase
Phase 1/2
Status
Active
Company
Lin BioScience

About Lin BioScience

Taiwan‑based biotech developing oral small‑molecule drugs for eye disease, cancer and metabolic disorders, with multiple FDA‑designated clinical programs.

View full company profile

Therapeutic Areas

OphthalmologyOncologyMetabolic Disease

Other Acute Myeloid Leukemia Drugs

DrugCompanyPhase
AFM28AffimedPhase 1/2
AML (N-Act) AIBiostate AIDevelopment
Navtemadlin (KRT-232)Kartos TherapeuticsPhase 1/Phase 2
QL325QLSF BiotherapeuticsPhase 1
NPM1 Testing in AMLDiatech PharmacogeneticsCommercial
Joint Development for AMLOrdaos BioPre-clinical
DFP Oncology ProgramDelta-Fly PharmaPreclinical
NG-202Nanogen Pharmaceutical BiotechnologyPreclinical
RG6356 (RO7434656)Chugai PharmaceuticalPhase III
AL8326Shanghai Allist PharmaceuticalsPhase II